Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Hartmut Döhner; Courtney D DiNardo; Frederick R Appelbaum; Charles Craddock; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Lucy A Godley; Robert P Hasserjian; Richard A Larson; Ross L Levine; Yasushi Miyazaki; Dietger Niederwieser; Gert Ossenkoppele; Christoph Röllig; Jorge Sierra; Eytan M Stein; Martin S Tallman; Hwei-Fang Tien; Jianxiang Wang; Agnieszka Wierzbowska; Andrew H Wei; Bob Löwenberg

doi:10.1182/blood.2024025409

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood. 2024 Nov 21;144(21):2169-2173. doi: 10.1182/blood.2024025409.

Authors

Hartmut Döhner¹, Courtney D DiNardo², Frederick R Appelbaum³, Charles Craddock⁴, Hervé Dombret⁵, Benjamin L Ebert⁶, Pierre Fenaux⁷, Lucy A Godley⁸, Robert P Hasserjian⁹, Richard A Larson¹⁰, Ross L Levine¹¹, Yasushi Miyazaki¹², Dietger Niederwieser¹³, Gert Ossenkoppele¹⁴, Christoph Röllig¹⁵, Jorge Sierra¹⁶, Eytan M Stein¹¹, Martin S Tallman¹¹, Hwei-Fang Tien¹⁷, Jianxiang Wang¹⁸, Agnieszka Wierzbowska¹⁹, Andrew H Wei²⁰, Bob Löwenberg²¹

Affiliations

¹ Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
³ Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.
⁴ University of Warwick Trials Unit, Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
⁵ Department of Hematology, Saint-Louis Institute for Research, Université Paris Cité, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁶ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
⁷ Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université de Paris Cité, Paris, France.
⁸ Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
⁹ Department of Pathology, Massachusetts General Hospital, Boston, MA.
¹⁰ Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL.
¹¹ Department of Medicine, Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
¹² Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
¹³ Division of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany.
¹⁴ Department of Hematology, Amsterdam University Medical Center, Location Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
¹⁵ Department of Internal Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
¹⁶ Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
¹⁷ Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
¹⁸ Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
¹⁹ Department of Hematology, Medical University of Lodz, Lodz, Poland.
²⁰ Department of Haematology, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia.
²¹ Department of Hematology, Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

PMID: 39133932
DOI: 10.1182/blood.2024025409

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

MeSH terms

Adult
Genetic Predisposition to Disease
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / therapy
Risk Assessment
Risk Factors